FDA Experts Resist Trump Plan to Expand Peptide Access

WHO:

NPR - Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, said his company would likely compound only one of the six peptides and could not meet demand.

NPR - Public Citizen’s Health Research Group Director Dr. Robert Steinbrook said the policy “undermined the FDA and threatened public health.”

NPR - Shabbir Safda, executive director of the Partnership for Safe Medicines, said the decision leaves Americans in a “grey area” about peptide safety.

CNN - Health Secretary Robert F. Kennedy Jr. supported expanded access to peptides and called himself a “big fan”; he said he used BPC-157 to treat a muscle injury.

ABC News - Six people familiar with the policy’s development said most FDA scientific staff opposed the effort and had limited input; they spoke anonymously about confidential government deliberations.

Fast Company - FDA drug staffers warned that easing restrictions could undermine the agency’s mission of keeping unproven health products off the U.S. market.

NBC News Health - The Department of Health and Human Services (HHS) is allowing compounding pharmacies temporary permission to make six peptides while work continues on a formal rule change.

ABC News - The Alliance for Pharmacy Compounding supported safety measures included in the proposal and had met with White House officials.

WHAT:

CNN - FDA scientists provided technical assistance in drafting the HHS plan, including safeguards requiring compounders to verify peptides’ chemical identities and collect side-effect information for safety analysis.

ABC News - Some peptides occur naturally in the body and trigger hormones involved in growth, metabolism and healing; drug companies have brought other peptides to market as diabetes and weight-loss medications.

ABC News - Both BPC-157 and TB-500 are considered doping substances by international sports authorities.

ABC News - The document underwent regulatory review at the White House, described as typically the final step before publication.

NPR - The six peptides named are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500; the article associates them respectively with ulcerative colitis, insomnia, wound healing, metabolic health, migraine and wound healing.

NPR - The policy applies to smaller 503A compounding pharmacies, not larger 503B outsourcing facilities.

NPR - The Partnership for Safe Medicines filed a citizen petition asking the FDA to disregard the advisory committee’s recommendation to allow compounding the six peptides.

NPR - FDA advisers voted for expanded access to six peptides, while FDA scientists recommended against lifting the restrictions.

NPR - The policy does not change the peptides’ legal status.

ABC News - The policy document covers certain injectable peptides popular in the wellness industry.

ABC News - HHS’s proposed approach avoids a direct confrontation with FDA staff by directing the agency not to enforce certain rules.

ABC News - Compounding has grown from a niche business into a multibillion-dollar industry serving doctors, clinics and hospitals.

CNN - HHS’s plan directs the FDA not to take action against specialty pharmacies selling certain peptides, including BPC-157, TB-500 and KPV. The policy concerns injectable products promoted for muscle building, injury healing and increased energy.

ABC News - The peptides have not undergone FDA review for safety and effectiveness and would otherwise be considered illegal drugs. BPC-157 and TB-500 are considered doping substances by international sports authorities.

Fast Company - HHS initially wanted the FDA to issue a regulation deeming BPC-157 and other peptides safe for compounding; after FDA objections, HHS switched to a non-enforcement approach.

ABC News - FDA staff proposed safeguards: pharmacies must source ingredients from FDA-registered facilities, verify peptide chemical identities and collect side-effect information for safety analysis.

WHERE:

ABC News - The policy underwent review at the White House. Some peptide users obtain online vials from chemical manufacturers in China rather than through doctors or pharmacies.

CNN - A 2012 fungal meningitis outbreak linked to contaminated injections from a Massachusetts compounding pharmacy heightened FDA attention to compounding safety.

WHEN:

ABC News - The FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded in 2023.

CNN - At a July meeting, FDA staff reiterated that more than half a dozen peptides under reconsideration remained unproven for safety and effectiveness.

WHY:

NPR - Public Citizen said Kennedy acted unilaterally rather than through the typical rulemaking process.

ABC News - The FDA cited risks including allergic reactions, kidney damage and tumor growth in listing peptides that should not be compounded.

CNN - Kennedy argued U.S. pharmacies should be allowed to sell peptides because Americans are turning to “gray market” products imported from China and other countries.

HOW:

ABC News - Six people familiar with the policy’s development told The Associated Press that the policy would direct the FDA not to take action against specialty pharmacies selling the peptides.

ABC News - The Alliance for Pharmacy Compounding said the proposed safety measures would provide a “more accountable alternative” and place patients in a system with pharmacy standards, regulatory oversight and serious adverse-event reporting.

BBC - The draft policy was prepared by the health secretary’s office rather than the FDA. After official publication, it will have a two-week public comment period.

ABC News - Three people familiar with the policy’s development said it would direct the FDA not to take action against specialty pharmacies selling the peptides.

NPR - Olympia’s smaller compounding facility would need to be prepared before it could make peptides; ingredient suppliers and pharmacies also need to verify that ingredients meet the policy’s requirements.

ABC News - Six people familiar with the policy’s development spoke anonymously to The Associated Press about confidential government deliberations.

CNN - Two people familiar with the policy’s development said the new document marked a step back from HHS’s original plans.

Fast Company - Sellers may label peptides “for research use only”; the FDA does not regulate research chemicals.

ABC News - Federal law gives HHS authority over drug regulations, which are delegated to the FDA; HHS rarely leads policy drafting for the compounding industry.

(UPDATED October 29, 2026 17:01 UTC)

HHS is allowing compounding pharmacies temporary permission to make six injectable peptides, directing the FDA not to enforce certain rules while officials work on a formal policy; the move does not change the peptides’ legal status. The products have not been reviewed by the FDA for safety and effectiveness, and the agency has warned of risks including allergic reactions, kidney damage and tumor growth, while safeguards would require pharmacies to verify ingredients and report side effects. Health Secretary Robert F. Kennedy Jr. supports broader access, but FDA scientists and public health advocates warn the policy could undermine safety oversight, and a Florida pharmacy operator says his company may make only one peptide and would not meet demand.

(UPDATED October 29, 2026 13:02 UTC)

HHS is allowing smaller compounding pharmacies temporary permission to make six injectable peptides, directing the FDA not to enforce certain rules while a formal policy change is developed; the move does not change the peptides’ legal status. The substances, promoted for uses including healing and metabolism, have not been reviewed by the FDA for safety and effectiveness, and the agency has cited risks such as allergic reactions, kidney damage and tumor growth. Health Secretary Robert F. Kennedy Jr. supports expanded access, but FDA scientists opposed easing restrictions, while safety advocates warn the approach could put public health at risk.

(UPDATED October 29, 2026 07:02 UTC)

HHS is temporarily allowing smaller compounding pharmacies to make six injectable peptides by directing the FDA not to enforce certain restrictions, even though the products have not been reviewed for safety or effectiveness and their legal status is unchanged. The move follows a split between FDA advisers who supported expanded access and agency scientists who opposed easing restrictions, citing potential risks including allergic reactions, kidney damage and tumor growth; Health Secretary Robert F. Kennedy Jr. has backed broader access, saying Americans are turning to unregulated products from abroad. Safety advocates say the policy weakens FDA oversight, while one Florida pharmacy says it may be able to compound only one peptide and could not meet demand; BPC-157 and TB-500 are also considered doping substances by international sports authorities.

(UPDATED October 29, 2026 02:59 UTC)

HHS is allowing smaller compounding pharmacies temporary permission to make six injectable peptides, directing the FDA not to enforce certain restrictions while work continues on a formal rule change. The peptides have not been reviewed by the FDA for safety or effectiveness, and the agency has cited risks including allergic reactions, kidney damage and tumor growth; FDA scientists opposed easing restrictions, while Health Secretary Robert F. Kennedy Jr. supports expanded access. Safety advocates say the policy weakens FDA oversight and leaves consumers in a grey area, while a pharmacy operator said his company could likely make only one peptide and would not meet demand.

(UPDATED October 29, 2026 01:14 UTC)

HHS is giving smaller compounding pharmacies temporary permission to make six injectable peptides, directing the FDA not to enforce certain rules while a formal policy is developed; the move does not change the peptides’ legal status. The substances have not been reviewed by the FDA for safety or effectiveness, and agency staff warned of risks including allergic reactions, kidney damage and tumor growth, while Health Secretary Robert F. Kennedy Jr. backed wider access and said he had used BPC-157. FDA advisers supported expanded access, but agency scientists opposed lifting restrictions, and safety advocates say the policy leaves consumers in a grey area as pharmacies warn they may struggle to meet demand.

(UPDATED October 29, 2026 00:00 UTC)

Health Secretary Robert F. Kennedy Jr. is backing wider access to certain injectable peptides, and HHS is allowing compounding pharmacies temporary permission to make six of them while a formal rule change is developed. The policy directs the FDA not to enforce some restrictions on specialty pharmacies selling peptides including BPC-157, which Kennedy says he used for a muscle injury, even though the products have not been reviewed by the FDA for safety or effectiveness. FDA staff warned that easing restrictions could expose people to risks including allergic reactions, kidney damage and tumor growth, and proposed safeguards such as verifying ingredients and tracking side effects.

(UPDATED October 28, 2026 20:02 UTC)

HHS is allowing compounding pharmacies temporary permission to make six peptides, including BPC-157, while pursuing a formal rule change; the plan directs the FDA not to act against certain sellers. Health Secretary Robert F. Kennedy Jr. backed expanded access and said he used BPC-157 for a muscle injury, even though the peptides have not been FDA-reviewed for safety or effectiveness and the agency has warned of risks including allergic reactions, kidney damage and tumor growth. FDA scientific staff largely opposed easing restrictions and proposed safeguards such as verifying ingredients and tracking side effects, while HHS shifted to a non-enforcement approach after FDA objections.